Genmab Acquires Rights for 16 Cancer Targets
Genmab purchased all of Europroteome's rights, including patent applications and know how, and does not owe anything further to the insolvency estate. There are no milestone or royalty obligations.
Genmab has started generating human antibodies to a unique target highly expressed on colon carcinomas.
"These rights give Genmab access to numerous cancer targets, including ones for colon cancer, providing the opportunity to further build our pre-clinical pipeline," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
The acquisition of these rights does not influence Genmab's financial guidance for 2005.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous